INNATE HOST DEFENSE FUNCTIONS OF SECRETORY LEUCOPROTEASE INHIBITOR

REFERENCES

• Doumas S, Kolokotronis A, Stefanopoulos P: Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005;73:1271–1274.
   PubMed Web of Science ®Google Scholar
• Hochstrasser K, Reichert R, Schwartz S, Werle E: Isolation and characterisation of a protease inhibitor from human bronchial secretion. Hoppe-Seyler's Z Physiol Chem. 1972;353:221–226.
   PubMedGoogle Scholar
• Ohlsson K, Tegner H: Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor. Scand J Clin Lab Invest. 1976;36:437–445.
   PubMed Web of Science ®Google Scholar
• Tegner H: Quantitation of human granulocyte protease inhibitors in non-purulent bronchial lavage fluids. Acta Oto-Laryngol. 1978;85:282–289.
   PubMed Web of Science ®Google Scholar
• Thompson RC, Ohlsson K: Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA. 1986;83:6692–6696.
   PubMed Web of Science ®Google Scholar
• Schalkwijk J, Wiedow O, Hirose S: The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J. 1999;340:569–577.
   PubMed Web of Science ®Google Scholar
• Clauss A, Lilja H, Lundwall A: The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun. 2005;333:383–389.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Simpson KJ, Shaw DC, Nicholas KR: The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling. J Mol Graph Model. 1999;17:106–113, 134–136.
   PubMed Web of Science ®Google Scholar
• Clauss A, Lilja H, Lundwall A: A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J. 2002;368:233–242.
   PubMed Web of Science ®Google Scholar
• McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456–464.
   PubMed Web of Science ®Google Scholar
• Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, McElvaney NG: Gathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001;276:33345–33352.
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Taggart CC: Antiproteases. In: Barnes P, ed. Chronic Obstructive Pulmonary Disease Cellular and Molecular Mechanisms. Boca Raton, FL: Taylor Francis; 2005:343–365.
   Google Scholar
• Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, Wright CD, Weyant MJ, Hydo L, Reeves F, Shiloh MU, Ding A: Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med. 2000;28:1276–1282.
   PubMed Web of Science ®Google Scholar
• Sponer M, Nick HP, Schnebli HP: Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. Biol Chem Hoppe Seyler. 1991;372:963–970.
   PubMed Web of Science ®Google Scholar
• Draper D, Donohoe W, Mortimer L, Heine RP: Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis. 1998;178:815–819.
   PubMed Web of Science ®Google Scholar
• Greene C, Taggart C, Lowe G, Gallagher P, McElvaney N, O'Neill S: Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia. J Infect Dis. 2003;188:769–776.
   PubMed Web of Science ®Google Scholar
• Gompertz S, Bayley DL, Hill SL, Stockley RA: Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax. 2001;56:36–41.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr, Shapiro SD, Elias JA: Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000;192:1587–1600.
   PubMed Web of Science ®Google Scholar
• Jin FY, Nathan C, Radzioch D, Ding A: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997;88:417–426.
   PubMed Web of Science ®Google Scholar
• Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH: Antibacterial activity of antileukoprotease. Infect Immun. 1996;64:4520–4524.
   PubMed Web of Science ®Google Scholar
• Williams SE, Brown TI, Roghanian A, Sallenave J-M: SLPI and elafin: one glove, many fingers. Clin Sci. 2006;110:21–35.
   PubMed Web of Science ®Google Scholar
• Wiedow O, Harder J, Bartels J, Streit V, Christophers E: Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem Biophys Res Commun. 1998;248:904–909.
   PubMed Web of Science ®Google Scholar
• McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood. 1997;90:1141–1149.
   PubMed Web of Science ®Google Scholar
• Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2004;200:1337–1346.
   PubMed Web of Science ®Google Scholar
• Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM: Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest. 1997;99:894–900.
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG: Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90:1296–1301.
   PubMed Web of Science ®Google Scholar
• Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, Ward PA: Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol. 1999;154:239–247.
   PubMed Web of Science ®Google Scholar
• Mulligan MS, Lentsch AB, Huber-Lang M, Guo RF, Sarma V, Wright CD, Ulich TR, Ward PA: Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol. 2000;156:1033–1039.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Mori Y, Hagiwara K, Suzuki T, Sakakibara T, Kikuchi T, Igarashi T, Ebina M, Abe T, Miyazaki J, Takai T, Nukiwa T: Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med. 2003;197:669–674.
   PubMed Web of Science ®Google Scholar
• Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, Ding A, Knowles DM, Santini PA, Cerutti A: Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294–303.
   PubMed Web of Science ®Google Scholar
• Ding A, Thieblemont N, Zhu J, Jin F, Zhang J, Wright S: Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages. Infect Immun. 1999;67:4485–4489.
   PubMed Web of Science ®Google Scholar
• Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O'Neill SJ, McElvaney NG: Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med. 2005;202:1659–1668.
   PubMed Web of Science ®Google Scholar
• Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM: Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol. 2004;172:4535–4544.
   PubMed Web of Science ®Google Scholar
• Greene CM, McElvaney NG, O'Neill SJ, Taggart CC: Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun. 2004;72:3684–3687.
   PubMed Web of Science ®Google Scholar
• Taggart CC, Greene CM, McElvaney NG, O'Neill S: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem. 2002;277:33648–33653.
   PubMed Web of Science ®Google Scholar
• Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR: Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. J Biol Chem. 1999;274:787–794.
   PubMed Web of Science ®Google Scholar
• Hu X: Proteolytic signaling by TNFalpha: caspase activation and IkappaB degradation. Cytokine. 2003;21:286–294.
   PubMed Web of Science ®Google Scholar
• Barkett M, Xue D, Horvitz HR, Gilmore TD: Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem. 1997;272:29419–29422.
   PubMed Web of Science ®Google Scholar